Status:
NOT_YET_RECRUITING
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
GE Healthcare
Conditions:
Lu-177 PSMA
Eligibility:
MALE
Phase:
NA
Brief Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Detailed Description
Primary Objectives • To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function. Secondary Objectives * To compa...
Eligibility Criteria
Inclusion
- Eligibility Criteria
- Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L.
- Participants who agree to be imaged multiple times as defined in the study protocol.
- Exclusion Criteria
- Pluvicto therapy patients without renal or marrow function complications
- Participants who do not wish to be imaged multiple times as per the study protocol.
- Women and children since this is treatment for prostate cancer.
Exclusion
Key Trial Info
Start Date :
February 13 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT07169825
Start Date
February 13 2026
End Date
September 1 2028
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030